FIELD: biotechnology.
SUBSTANCE: group of inventions including a chimeric antisense oligonucleotide for the treatment or prevention of hepatitis B virus (HBV), a pharmaceutical composition for the treatment of hepatitis, a method of treating a subject with HBV, a method of inhibiting HBV gene expression in a cell, a method of lowering the level of HBV antigen in a subject infected with HBV are described. In one embodiment, the chimeric antisense oligonucleotide is represented by the following formula (VI): 5` X-Y-Z 3` (VI), where X-Y-Z is a chimeric oligonucleotide and the total length with X-Y-E is 18 to 22 nucleosides.
EFFECT: invention expands the arsenal of agents for the treatment or prevention of hepatitis B virus (HBV).
19 cl, 27 dwg, 52 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| AGENTS FOR RNAi, COMPOSITIONS AND METHODS OF THEIR USE FOR THE TREATMENT OF DISEASES ASSOCIATED WITH TRANSTHYRETIN (TTR) | 2012 |
|
RU2804776C2 |
| MIRNA STRUCTURES WITH HIGH ACTIVITY AND REDUCED EXPOSURE OUTSIDE THE TARGET | 2016 |
|
RU2788030C2 |
| OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATED TO THEM | 2016 |
|
RU2797833C1 |
| COMPOSITIONS AND METHODS FOR REDUCING TAU EXPRESSION | 2016 |
|
RU2747734C2 |
| COMPOSITIONS AND METHODS FOR REDUCING TAU EXPRESSION | 2016 |
|
RU2777570C2 |
| MODULATING POLYNUCLEOTIDES | 2015 |
|
RU2719192C2 |
| GENE EXPRESSION REGULATION SYSTEM | 2020 |
|
RU2825581C1 |
| COMPOSITIONS AND METHODS OF TREATING HEMOGLOBINOPATHIES | 2016 |
|
RU2812491C2 |
| MODULATING POLYNUCLEOTIDES | 2015 |
|
RU2749882C2 |
| DELIVERY, USE AND USE IN THERAPY OF CRISPR-CAS SYSTEMS AND COMPOSITIONS FOR TARGETED ACTION ON DISORDERS AND DISEASES USING VIRAL COMPONENTS | 2014 |
|
RU2716421C2 |
